Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial.

Malhotra R, Katz R, Weiner DE, Levey AS, Cheung AK, Bostom AG, Ix JH.

Am J Hypertens. 2019 Aug 14;32(9):816-823. doi: 10.1093/ajh/hpz095.

PMID:
31179500
2.

Physical Activity and Cardiovascular Risk among Kidney Transplant Patients.

Kang AW, Garber CE, Eaton CB, Risica PM, Bostom AG.

Med Sci Sports Exerc. 2019 Jun;51(6):1154-1161. doi: 10.1249/MSS.0000000000001886.

PMID:
30629045
3.

Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.

Weiner DE, Park M, Tighiouart H, Joseph AA, Carpenter MA, Goyal N, House AA, Hsu CY, Ix JH, Jacques PF, Kew CE, Kim SJ, Kusek JW, Pesavento TE, Pfeffer MA, Smith SR, Weir MR, Levey AS, Bostom AG.

Am J Kidney Dis. 2019 Jan;73(1):51-61. doi: 10.1053/j.ajkd.2018.05.015. Epub 2018 Jul 20.

PMID:
30037726
4.

Hypothesis: Potential Utility of Serum and Urine Uromodulin Measurement in Kidney Transplant Recipients?

Bostom AG, Steubl D, Friedman AN.

Transplant Direct. 2017 Oct 6;3(11):e219. doi: 10.1097/TXD.0000000000000737. eCollection 2017 Nov. Review.

5.

Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study.

Kalil RS, Carpenter MA, Ivanova A, Gravens-Mueller L, John AA, Weir MR, Pesavento T, Bostom AG, Pfeffer MA, Hunsicker LG.

Am J Kidney Dis. 2017 Dec;70(6):762-769. doi: 10.1053/j.ajkd.2017.06.013. Epub 2017 Aug 9.

PMID:
28801121
6.

Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS.

Am J Transplant. 2017 Sep;17(9):2390-2399. doi: 10.1111/ajt.14258. Epub 2017 Mar 30.

7.

More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.

Bostom AG, Merhi B, Walker J, Robinson-Bostom L.

World J Transplant. 2016 Dec 24;6(4):658-664. doi: 10.5500/wjt.v6.i4.658. Review.

8.

B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.

Jarolim P, Claggett BL, Conrad MJ, Carpenter MA, Ivanova A, Bostom AG, Kusek JW, Hunsicker LG, Jacques PF, Gravens-Mueller L, Finn P, Solomon SD, Weiner DE, Levey AS, Pfeffer MA.

Transplantation. 2017 Jan;101(1):182-190. doi: 10.1097/TP.0000000000001080.

9.

Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.

Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, Diamantidis CJ; FAVORIT Study Investigators.

Transplantation. 2015 May;99(5):1003-8. doi: 10.1097/TP.0000000000000454.

10.

Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.

Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW.

Clin Transplant. 2012 Jul-Aug;26(4):E438-46. doi: 10.1111/j.1399-0012.2012.01676.x. Epub 2012 Jul 9.

11.

Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.

Weiner DE, Carpenter MA, Levey AS, Ivanova A, Cole EH, Hunsicker L, Kasiske BL, Kim SJ, Kusek JW, Bostom AG.

Am J Transplant. 2012 Sep;12(9):2437-45. doi: 10.1111/j.1600-6143.2012.04101.x. Epub 2012 May 17.

12.

Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.

Bostom AG, Maclean AA, Maccubbin D, Tipping D, Giezek H, Hanlon WA.

J Clin Lipidol. 2011 Jul-Aug;5(4):281-7. doi: 10.1016/j.jacl.2011.03.455. Epub 2011 May 13.

PMID:
21784373
13.

Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.

Ix JH, Ganjoo P, Tipping D, Tershakovec AM, Bostom AG.

Am J Kidney Dis. 2011 Jun;57(6):963-5. doi: 10.1053/j.ajkd.2011.03.010. Epub 2011 Apr 15. No abstract available. Erratum in: Am J Kidney Dis. 2011 Oct;58(4):688. Dosage error in article text.

PMID:
21496982
14.

Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.

Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11.

15.

Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia.

Hu S, Shearer GC, Steffes MW, Harris WS, Bostom AG.

Am J Kidney Dis. 2011 Jan;57(1):181-2. doi: 10.1053/j.ajkd.2010.06.029. Epub 2010 Oct 8. No abstract available.

PMID:
20888102
16.

New evidence for the phosphorus-lowering effects of niacin.

Bostom AG.

Am J Kidney Dis. 2010 Jul;56(1):185. doi: 10.1053/j.ajkd.2010.03.032. No abstract available.

PMID:
20620683
17.

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG.

Clin J Am Soc Nephrol. 2010 Apr;5(4):582-9. doi: 10.2215/CJN.07341009. Epub 2010 Mar 18.

18.

Binder blinders-niacin of omission?

Bostom AG.

Am J Kidney Dis. 2010 Apr;55(4):628-30. doi: 10.1053/j.ajkd.2009.12.015. Epub 2010 Jan 15. No abstract available.

PMID:
20079958
19.

Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.

Bostom AG, Carpenter MA, Hunsicker L, Jacques PF, Kusek JW, Levey AS, McKenney JL, Mercier RY, Pfeffer MA, Selhub J; FAVORIT Study Investigators.

Am J Kidney Dis. 2009 Jan;53(1):121-8. doi: 10.1053/j.ajkd.2008.08.010. Epub 2008 Nov 20.

20.

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.

Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J; FAVORIT Investigators.

Am Heart J. 2006 Sep;152(3):448.e1-7.

PMID:
16923411
21.

Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group.

J Am Soc Nephrol. 2005 Nov;16(11):3397-402. Epub 2005 Sep 14.

22.

C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group.

Kidney Int. 2005 Aug;68(2):773-8.

23.

Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG.

Atherosclerosis. 2004 Jan;172(1):121-5.

PMID:
14709365
24.

The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study.

Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D.

Am J Kidney Dis. 2003 Feb;41(2):442-6.

PMID:
12552508
25.

Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study.

Jacques PF, Bostom AG, Selhub J, Rich S, Ellison RC, Eckfeldt JH, Gravel RA, Rozen R; National Heart, Lung and Blood Institute, National Institutes of Health.

Atherosclerosis. 2003 Jan;166(1):49-55.

PMID:
12482550
26.

Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk.

Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I, Mittleman MA, Selhub J.

Thromb Haemost. 2002 Nov;88(5):799-804.

PMID:
12428097
27.

Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid.

Ghandour H, Bagley PJ, Shemin D, Hsu N, Jacques PF, Dworkin L, Bostom AG, Selhub J.

Kidney Int. 2002 Dec;62(6):2246-9.

28.

Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy.

Friedman AN, Hunsicker LG, Selhub J, Bostom AG; Collaborative Study Group.

Diabetes Care. 2002 Nov;25(11):2037-41.

PMID:
12401753
29.
30.

Hyperhomocysteinemia in renal transplant recipients.

Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG.

Am J Transplant. 2002 Apr;2(4):308-13. Review.

31.

B vitamins and restenosis after coronary angioplasty.

Bostom AG, Sharaf B.

N Engl J Med. 2002 Apr 4;346(14):1093-5. No abstract available.

PMID:
11936123
32.

Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour.

Bostom AG, Jacques PF, Liaugaudas G, Rogers G, Rosenberg IH, Selhub J.

Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):488-91.

PMID:
11884295
33.

Cost-effectiveness of homocysteine-lowering therapy to prevent coronary heart disease.

Bostom AG.

JAMA. 2002 Jan 9;287(2):190; author reply 191-2. No abstract available.

PMID:
11779257
34.

Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis.

Friedman AN, Bostom AG, Levey AS, Rosenberg IH, Selhub J, Pierratos A.

J Am Soc Nephrol. 2002 Jan;13(1):265-8.

35.

Effects of fenofibrate and gemfibrozil on plasma homocysteine.

Bostom AG.

Lancet. 2001 Nov 24;358(9295):1811-2. No abstract available.

PMID:
11734262
36.

Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate.

Bostom AG, Kronenberg F, Jacques PF, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Schwenger V, Riegler P, Selhub J.

Atherosclerosis. 2001 Nov;159(1):219-23.

PMID:
11689224
37.

Treatment of hyperhomocysteinemia in end-stage renal disease.

Shemin D, Bostom AG, Selhub J.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S91-4. Review.

PMID:
11576930
38.

The kidney and homocysteine metabolism.

Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH.

J Am Soc Nephrol. 2001 Oct;12(10):2181-9. Review.

39.

Serum cystatin C is an independent predictor of total homocysteine levels in stable Korean renal transplant recipients with normal serum creatinine.

Han H, Dwyer JT, Selhub J, Jacques PF, Houser RF, Park JH, Kim YS, Bang BK, Kim S, Jung KA, Chang YK, Bostom AG.

J Ren Nutr. 2001 Jul;11(3):149-54.

PMID:
11466665
40.

Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour.

Bostom AG, Selhub J, Jacques PF, Rosenberg IH.

Ann Intern Med. 2001 Jul 17;135(2):133-7.

PMID:
11453713
41.

Residual renal function and mortality risk in hemodialysis patients.

Shemin D, Bostom AG, Laliberty P, Dworkin LD.

Am J Kidney Dis. 2001 Jul;38(1):85-90.

PMID:
11431186
42.

Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification.

Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH.

Public Health Rev. 2000;28(1-4):117-45.

PMID:
11411265
43.

The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine.

Weisberg IS, Jacques PF, Selhub J, Bostom AG, Chen Z, Curtis Ellison R, Eckfeldt JH, Rozen R.

Atherosclerosis. 2001 Jun;156(2):409-15.

PMID:
11395038
44.

Chronic renal transplantation: a model for the hyperhomocysteinemia of renal insufficiency.

Bostom AG, Kronenberg F, Gohh RY, Schwenger V, Kuen E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Ritz E, Selhub J.

Atherosclerosis. 2001 May;156(1):227-30.

PMID:
11369018
45.
46.

Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort.

Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J.

Am J Clin Nutr. 2001 Mar;73(3):613-21.

PMID:
11237940
47.

Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey.

Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH.

Atherosclerosis. 2001 Mar;155(1):195-200.

PMID:
11223442
48.

Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients.

Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massy ZA, Jacques PF, Dworkin L, Selhub J.

Kidney Int Suppl. 2001 Feb;78:S246-52.

49.

Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients.

Yango A, Shemin D, Hsu N, Jacques PF, Dworkin L, Selhub J, Bostom AG.

Kidney Int. 2001 Jan;59(1):324-7.

50.

Determinants of plasma total homocysteine levels in Korean chronic renal transplant recipients.

Han H, Dwyer JT, Selhub J, Jacques PF, Park JH, Kim YS, Bang BK, Bostom AG.

J Ren Nutr. 2000 Oct;10(4):202-7.

PMID:
11070148

Supplemental Content

Loading ...
Support Center